Fenobam - Autism Therapeutics

Drug Profile

Fenobam - Autism Therapeutics

Alternative Names: AT002; Fenobam hydrochloride; NPL-2009

Latest Information Update: 30 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator FRAXA Research Foundation; Neuropharm
  • Class Chlorobenzenes; Imidazoles; Small molecules; Urea compounds
  • Mechanism of Action Metabotropic glutamate receptor 5 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fragile X syndrome
  • New Molecular Entity No

Highest Development Phases

  • No development reported Fragile X syndrome

Most Recent Events

  • 30 Sep 2015 No recent reports of development identified - Phase-I/II for Fragile X syndrome in USA (PO)
  • 21 Dec 2011 Autism Therapeutics acquires Neuropharm
  • 07 Jan 2009 Pharmacokinetics, safety and efficacy data from a phase I/II trial in Fragile X Syndrome released by Neuropharma ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top